Efficacy of APX2039 in a Rabbit Model of Cryptococcal Meningitis

Area of Science:

• Mycology and Infectious Diseases
• Pharmacology and Drug Development

Background:

• Cryptococcal meningitis (CM) is a life-threatening fungal infection with limited treatment options.
• Existing therapies for CM have significant limitations and associated toxicities.
• Novel antifungal agents are urgently needed to combat CM morbidity and mortality.

Purpose of the Study:

• To evaluate the efficacy of APX2039, a novel Gwt1 inhibitor, in preclinical models of CM.
• To assess the pharmacokinetic properties and fungicidal activity of APX2039 in vivo.
• To compare the efficacy of APX2039 with existing antifungal drugs in CM models.

Main Methods:

• Efficacy of APX2039 was tested in mouse and rabbit models of cryptococcal meningitis.
• Fungal burden in lungs and brain (mouse) and cerebrospinal fluid (CSF) (rabbit) was quantified.
• Pharmacokinetic analysis and mathematical modeling were used to correlate drug exposure with antifungal activity.

Main Results:

• APX2039 significantly reduced fungal burden in the brain and lungs of mice compared to controls and other agents.
• Oral APX2039 in rabbits led to rapid CSF fungal clearance, achieving undetectable levels by day 10.
• APX2039 exhibited superior effective fungicidal activity (EFA) in rabbits (-0.66 log10 CFU/mL/day) compared to amphotericin B (-0.33 log10 CFU/mL/day) and human clinical outcomes (-0.4 log10 CFU/mL/day).

Conclusions:

• APX2039 demonstrates potent in vivo antifungal activity against Cryptococcus in preclinical CM models.
• The drug exhibits favorable pharmacokinetics, including significant central nervous system penetration.
• APX2039 is a promising candidate for oral fungicidal monotherapy in human cryptococcal meningitis treatment.